MedTrace Logo

Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell

NCT05784415 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-02-02

No results posted yet for this study

Summary

This protocol will develop an observational cohort of PLWH who have been or are being treated with CAR19 therapy outside of an AMC clinical trial. Following regulatory approval of this protocol, sites will be asked to capture information of participants, who carry a diagnosis of HIV disease AND received CAR19 therapy outside of a clinical trial between August 30, 2017 and August 31, 2021. Data captured will include data points are available as part of standard of care for participants undergoing CAR19 therapy. AMC investigators, as well as non-AMC investigators will identify eligible participants to the CIBMTR, who in turn will provide the AMC statistical center with de-identified data

Conditions

  • Leukemia
  • Leukemia, Lymphoblastic
  • Lymphoma, Large B-Cell, Diffuse
  • Follicular Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, Follicular
  • Lymphoma, Non-Hodgkin
  • HIV Infections
  • HIV Associated Lymphoma
  • HIV Disease; Lymphoma

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-22
Primary Completion
2024-11-14
Completion
2024-11-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05784415 on ClinicalTrials.gov